Norton J A, Jensen R T
Surgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
World J Surg. 1991 Jan-Feb;15(1):151-9. doi: 10.1007/BF01658992.
In the last 10 years, there have been a number of major advances that have markedly changed the management of patients with Zollinger-Ellison syndrome. These advances have been described recently in a number of excellent reviews. After reading each of these reviews, including our own, one is left generally with the impression that most of the important problems and particularly those involving surgery in the treatment of this disease have been resolved; however, in considering the possible problems to address in protocols in the coming years in our patients with Zollinger-Ellison syndrome followed at the National Institutes of Health, it became apparent to us that not only will surgery play an increasingly important role in the management of this disease, but that there are a number of major questions in which various aspects involving surgery are not resolved. Furthermore, resolution of a number of these areas will have applicability to the surgical treatment of other islet cell tumors. The purpose of this article is to call attention to these questions with the hope that other investigators may also consider these and specifically attempt to address some of these issues in the surgical treatment of Zollinger-Ellison syndrome in prospective studies.
在过去10年里，出现了一些重大进展，显著改变了卓-艾综合征患者的治疗方式。近期的一些优秀综述对这些进展进行了描述。在阅读了包括我们自己的综述在内的每一篇此类综述后，人们通常会留下这样的印象，即大多数重要问题，尤其是那些涉及该疾病外科治疗的问题已经得到解决；然而，在考虑美国国立卫生研究院随访的卓-艾综合征患者未来几年方案中可能要解决的问题时，我们明显意识到，手术不仅将在该疾病的治疗中发挥越来越重要的作用，而且在许多重大问题上，涉及手术的各个方面尚未得到解决。此外，其中一些领域问题的解决将适用于其他胰岛细胞瘤的外科治疗。本文旨在提请关注这些问题，希望其他研究人员也能考虑这些问题，并在卓-艾综合征外科治疗的前瞻性研究中专门尝试解决其中一些问题。
